Seven Fleet Capital Management LP Acquires 91,958 Shares of Roivant Sciences Ltd. $ROIV

Seven Fleet Capital Management LP lifted its holdings in shares of Roivant Sciences Ltd. (NASDAQ:ROIV) by 71.7% during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 220,126 shares of the company’s stock after purchasing an additional 91,958 shares during the period. Roivant Sciences accounts for 1.3% of Seven Fleet Capital Management LP’s holdings, making the stock its 17th biggest holding. Seven Fleet Capital Management LP’s holdings in Roivant Sciences were worth $7,790,000 as of its most recent SEC filing.

Other institutional investors also recently modified their holdings of the company. Fifth Third Bancorp raised its position in Roivant Sciences by 8.7% during the 1st quarter. Fifth Third Bancorp now owns 4,686 shares of the company’s stock worth $130,000 after purchasing an additional 376 shares during the last quarter. Bessemer Group Inc. lifted its holdings in Roivant Sciences by 21.8% during the 1st quarter. Bessemer Group Inc. now owns 2,465 shares of the company’s stock worth $69,000 after buying an additional 441 shares during the period. Fifth Third Wealth Advisors LLC grew its position in shares of Roivant Sciences by 4.6% in the 1st quarter. Fifth Third Wealth Advisors LLC now owns 10,166 shares of the company’s stock valued at $282,000 after buying an additional 445 shares during the last quarter. Versant Capital Management Inc grew its position in shares of Roivant Sciences by 13.9% in the 2nd quarter. Versant Capital Management Inc now owns 3,995 shares of the company’s stock valued at $141,000 after buying an additional 487 shares during the last quarter. Finally, Oregon Public Employees Retirement Fund increased its stake in shares of Roivant Sciences by 0.6% in the fourth quarter. Oregon Public Employees Retirement Fund now owns 87,152 shares of the company’s stock valued at $1,891,000 after buying an additional 500 shares during the period. Institutional investors own 64.76% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts recently commented on ROIV shares. Leerink Partners set a $42.00 price objective on Roivant Sciences in a research note on Thursday, May 21st. HC Wainwright boosted their price objective on Roivant Sciences from $34.00 to $41.00 and gave the company a “buy” rating in a research note on Friday, August 7th. Weiss Ratings restated a “sell (d-)” rating on shares of Roivant Sciences in a report on Wednesday, August 19th. Citigroup lifted their price objective on shares of Roivant Sciences from $42.00 to $46.00 and gave the company a “buy” rating in a research note on Monday, August 10th. Finally, TD Cowen restated a “buy” rating on shares of Roivant Sciences in a report on Thursday, August 6th. One investment analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Roivant Sciences has an average rating of “Moderate Buy” and a consensus price target of $35.14.

Roivant Sciences Stock Up 0.8%

NASDAQ ROIV opened at $36.75 on Thursday. Roivant Sciences Ltd. has a 52 week low of $11.85 and a 52 week high of $37.97. The business has a 50 day moving average price of $34.97 and a 200-day moving average price of $30.80. The company has a market cap of $26.55 billion, a price-to-earnings ratio of -69.34 and a beta of 1.12.

Roivant Sciences (NASDAQ:ROIV) last issued its earnings results on Friday, August 7th. The company reported ($0.26) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.30) by $0.04. Roivant Sciences had a negative return on equity of 22.94% and a negative net margin of 3,534.96%.The company had revenue of $1.44 million for the quarter, compared to analysts’ expectations of $2.06 million. On average, equities research analysts anticipate that Roivant Sciences Ltd. will post -2 earnings per share for the current year.

Insider Buying and Selling at Roivant Sciences

In other Roivant Sciences news, insider Mayukh Sukhatme sold 284,707 shares of the firm’s stock in a transaction on Monday, August 17th. The shares were sold at an average price of $36.25, for a total value of $10,320,628.75. Following the transaction, the insider directly owned 18,630,739 shares of the company’s stock, valued at approximately $675,364,288.75. This trade represents a 1.51% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Melissa B. Epperly sold 17,750 shares of Roivant Sciences stock in a transaction dated Monday, June 29th. The shares were sold at an average price of $34.38, for a total transaction of $610,245.00. Following the transaction, the director owned 16,474 shares of the company’s stock, valued at $566,376.12. This represents a 51.86% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders have sold 2,855,913 shares of company stock worth $100,107,258. Corporate insiders own 8.80% of the company’s stock.

Roivant Sciences Profile

Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.

The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women’s health.